Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration

a combination drug and fatty liver disease technology, applied in the direction of pharmaceutical delivery mechanism, drug composition, organic active ingredients, etc., can solve the problems of macrovesicular fat accumulation improvement, suppress the progression of cirrhosis, and improve the non-alcoholic fatty liver disease (nafld). the effect of normal liver recovery

Inactive Publication Date: 2019-11-07
MEDICO CONSL CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0034]According to the present invention, it is possible to recover normal liver and suppress progress to cirrhosi

Problems solved by technology

However, improvement of macrovesicular fat accumulation in liver tissue and balloon-like hypertrophy (ballooning) of the hepatocyte and cell inflammation infiltration characterized in non-alcoholic fat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration
  • Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration
  • Combination drug suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration

Examples

Experimental program
Comparison scheme
Effect test

example

[0062]The NASH model mice were assigned to four groups (eight mice per group) by body weight stratification random sampling method so that the average body weight is equal. The four groups are the zinc preparation (polaprezinc)+selenium preparation (sodium selenite) group, zinc preparation (polaprezinc) alone group, selenium preparation (sodium selenite) alone group, and control group. The route of administration was oral administration, and the period of administration was 28 days.

[0063]The number of administration was once a day. The dosage was 10 ml / kg body weight and was administrated using an oral zonde.

[0064]The dosages of each group are shown below.

TABLE 1NumberDoseofTest groupDosageConcentration(ml / kg)animalsControl00108Selenium prepara-150μg / kg15μg / ml108tion (sodiumselenite)Zinc preparation45.2mg / kg4.52mg / ml108(polap rezinc)Zinc preparation45.2 mg / kg +4.52 mg / ml +108(polaprezinc) +150 μg / kg15 μg / mlSelenium prepara-tion (sodiumselenite)

[0065]Blood was collected from the hear...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Problem to be Solved
To provide medicine and health food suitable for treatment and prevention for non-alcoholic fatty liver disease (NAFLAD) and/or non-alcoholic steatohepatitis (NASH) which are not involved with hepatic virus, and/or hepatic fatty degeneration.
Means for solving the problem
A combination drug suitable for treatment of non-alcoholic fatty liver disease (NAFLAD) and/or non-alcoholic steatohepatitis (NASH), and/or hepatic fatty degeneration, wherein the active ingredients are zinc preparation and selenium preparation.

Description

TECHNICAL FIELD[0001]The present invention is related to a pharmaceutical combination drug and health food suitable for treatment and prevention of non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH).[0002]Further in detail, the present invention is related to a combination drug of zinc preparation, especially polaprezinc, and selenium preparation, especially sodium selenite for treating non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH), and a combination drug of zinc preparation, especially polaprezinc, and selenium preparation, especially sodium selenite for treatment of diseases related or associated with non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH). It may contain zinc preparation, especially polaprezinc, and selenium preparation, especially sodium selenite defined in the present specification and combine one kind or plural kinds of other active substances, and the phar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/04A61K31/355A61K9/00A61P1/16
CPCA61P1/16A61K31/355A61K9/0053A61K33/04A23L33/16A61K31/4164A61K31/315A61K2300/00
Inventor KUBOTA, SATORUKONO, TORU
Owner MEDICO CONSL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap